Research News

---

Topic: Diagnosis (view all topics)

Tags for topic Diagnosis:

• 1cm-1.9cm
• Ductal Carcinoma In Situ
• Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ)
• Early-stage: Stage IA
• Early-stage: Stage IB
• Early-stage: Stage IIA
• Early-stage: Stage IIB
• Early-stage: Stage IIIA
• Estrogen Receptor Negative Cancer
• Estrogen Receptor Positive Cancer
• HER2/neu Negative Cancer
• HER2/neu Positive Cancer
• HER2 Overexpressing
• Invasive or Infiltrating Ductal Carcinoma
• Invasive or Infiltrating Lobular Carcinoma
• Less than 1cm
• Locally Advanced-stage: Stage IIIB
• Locally Advanced-stage: Stage IIIC
• Luminal A
• Luminal B
• Metastatic
• Metastatic/Advanced-stage: Stage IV
• Non-Metastatic
• Progesterone Receptor Negative Cancer
• Progesterone Receptor Positive Cancer
• Regional
• Triple Negative

View articles by month and year

• Mammostrat Test Helps Estimate Recurrence Risk and Make Treatment Decisions

  Published on October 16, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Positive Cancer, and Progesterone Receptor Positive Cancer

  A study shows that the Mammostrat test can offer more information on the risk of early-stage, hormone-receptor-positive breast cancer coming back in postmenopausal women and help make treatment decisions.

• Study Analyzes Breast Cancer Genetics, Finds Four Classes of Disease

  Published on September 25, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  Researchers have done the most thorough analysis of breast cancer genetics to date and found that there are four genetically distinct classes of the disease.

• Breast Cancer’s Hormone Receptor and HER2 Status Can Change After Diagnosis

  Published on June 20, 2012 at 12:00 am

  • Tags: Locally Advanced-stage: Stage IIIB, Locally Advanced-stage: Stage IIIC, Metastatic/Advanced-stage: Stage IV, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Positive Cancer, Metastatic, Non-Metastatic, Regional, Biopsy, FISH Test, IHC Test, Inform HER2 Dual ISH Test, SPoT-Light HER2 CISH, HER2/neu Negative Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...

• Women Older Than 65 Have Worse Outcomes After Breast Cancer Diagnosis

  Published on February 7, 2012 at 12:00 am

  • Tags: Progesterone Receptor Positive Cancer, Estrogen Receptor Positive Cancer, Non-Metastatic, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, and Early-stage: Stage IIIA

  A large study has found that women older than 65 diagnosed with early-stage, hormone-receptor-positive breast cancer had worse outcomes than younger women with similar diagnoses.

• Biopsy of Metastatic Cancer May Change Treatment Plan

  Published on June 7, 2010 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Biopsy, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  Research suggests that a breast cancer's characteristics may change if the cancer metastasizes, so doing a biopsy on metastatic cancer may make sense in some cases.

• Genomic Test Results Not Understood by Many Women

  Published on March 8, 2010 at 12:00 am

  • Tags: Progesterone Receptor Positive Cancer, Estrogen Receptor Positive Cancer, Non-Metastatic, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, MammaPrint, and Oncotype DX

  A small study found that about a third of women who had genomic testing didn't really understand the test results.

• New Guidelines for Early-Stage Breast Cancer Recommend Treatment Based on Individual Cancer Characteristics

  Published on June 18, 2009 at 12:00 am

  • Tags: Non-Metastatic, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  A large group of cancer experts created new guidelines for treating early-stage breast cancer; the guidelines recommend that chemotherapy, targeted therapies, radiation therapy, and hormonal therapy should be based on the characteristics of each individual cancer being treated.

• Biopsy of Metastatic Cancer Can Improve Treatment

  Published on March 18, 2009 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Biopsy, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  In some cases, certain "personality" factors of recurrent metastatic breast cancer -- hormone-receptor status and HER2 status -- can be different from the original breast cancer, which may affect treatment decisions.

• New Tool Can Help Predict Recurrence Risk

  Published on September 24, 2008 at 12:00 am

  • Tags: Non-Metastatic, Progesterone Receptor Positive Cancer, Estrogen Receptor Positive Cancer, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, and Early-stage: Stage IIIA

  A new tool that looks at four breast cancer characteristics seems to do a good job of predicting whether early-stage hormone-receptor-positive breast cancer is likely to come back (recurrence). The tool assessed recurrence in women diagnosed with early-stage hormone-receptor-positive breast cancer that had been treated with hormonal therapy before surgery.

• Even with New Treatments, No Improvement in Metastatic Breast Cancer Survival

  Published on September 9, 2008 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, Progesterone Receptor Negative Cancer, and Progesterone Receptor Positive Cancer

  A new study finds the average survival time after a diagnosis of metastatic breast cancer hasn't changed much since 1985.